<DOC>
	<DOCNO>NCT00222521</DOCNO>
	<brief_summary>This Study design determine whether treatment CFRD glargine insulin improve hemoglobin A1c , weight muscle mass compare traditional regimen bedtime NPH insulin .</brief_summary>
	<brief_title>Insulin Glargine Vs Standard Insulin Therapy</brief_title>
	<detailed_description>The majority cystic fibrosis ( CF ) patient survive beyond childhood , CF relate diabetes ( CFRD ) , due insulin deficiency , common . CFRD fast hyperglycemia occur 15 % adult CF patient . Standard insulin therapy rely primarily meal coverage rapid-acting insulin . Usually , basal insulin coverage provide overnight , modest dos NPH insulin . The practice provide minimal basal insulin CFRD base fact patient , unless acutely ill , able maintain relatively normal blood glucose level day without . In addition , anecdotal experience suggest daytime NPH insulin twice daily ultralente insulin frequently lead hypoglycemia CFRD patient . This practice , base practical clinical consideration , ignores establish relationship insulin deficiency clinical deterioration CFRD . BMI pulmonary function deteriorate much rapidly CF patient diabetes CF patient normal glucose tolerance . Insulin deficiency lead increase protein catabolism fatty acid turnover . The resulting loss weight lean body mass contribute pulmonary disease clinical decline . We hypothesize : 1 . Basal insulin coverage insulin glargine improve hemoglobin A1c , weight , muscle mass patient CFRD fast hyperglycemia , compare traditional regimen less basal insulin . 2 . Because peakless action insulin glargine , accomplish without serious hypoglycemia .</detailed_description>
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<criteria>1 . Inclusion Criteria 1 . CFRD fast hyperglycemia ( fast plasma glucose ≥126 mg/dl ) 1. . The diagnosis must make time patient his/her basal state health evidence acute exacerbation precede two month . ) . Acute exacerbation define page 9 . 2. . For patient onset diabetes precede 6 month , hemoglobin A1c must stable 3 month prior study entrance within 5 % ( 0.3 % A1c increment ) . 2 . Age ≥18 , postpubertal ( do growing , since change weight study endpoint ) 3 . Weight stable within 5 % previous 3 month measure CF clinic 4 . Willingness attend study visit engage regular phone email contact study diabetes nurse 5 . Glucocorticoids profound effect weight , thus wish minimize occurrence change steroid dos study period . Patients receive glucocorticoid therapy include protocol : 1. . They steroid dose precede six month , 2. . There plan change steroid dose next eight month . 2 . Exclusion Criteria 1 . Pregnancy plan become pregnant next eight month ( change pregnancy would cause study endpoint ) , 2 . Unwillingness / inability take multiple injection count carbohydrate , 3 . A history hypoglycemia unawareness ( rare CF ) , 4 . Plans start medication next 8 month might affect weight , testosterone Megace . Patients chronically take medication may include : 1. . They dose precede six month 2. . There plan change dose next eight month</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2005</verification_date>
	<keyword>Cystic Fibrosis</keyword>
	<keyword>Diabetes</keyword>
</DOC>